Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Consolidated Net Income (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Consolidated Net Income for 13 consecutive years, with -$58.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 1.63% to -$58.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$285.0 million, a 38.82% increase, with the full-year FY2025 number at -$285.0 million, up 38.82% from a year prior.
  • Consolidated Net Income was -$58.4 million for Q4 2025 at Madrigal Pharmaceuticals, up from -$111.1 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$42.2 million in Q2 2025 to a low of -$152.0 million in Q2 2024.
  • A 5-year average of -$83.1 million and a median of -$75.1 million in 2023 define the central range for Consolidated Net Income.
  • Peak YoY movement for Consolidated Net Income: crashed 91.87% in 2024, then soared 72.21% in 2025.
  • Madrigal Pharmaceuticals' Consolidated Net Income stood at -$64.5 million in 2021, then crashed by 33.08% to -$85.9 million in 2022, then crashed by 30.6% to -$112.2 million in 2023, then soared by 47.04% to -$59.4 million in 2024, then increased by 1.63% to -$58.4 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Consolidated Net Income are -$58.4 million (Q4 2025), -$111.1 million (Q3 2025), and -$42.2 million (Q2 2025).